Similar results were obtained using engineered T cells, directed against HCV antigens where recognition of HCC cells expressing HCV NS3 protein was achieved in vitro and the regression of the tumour mass of an HCV-positive HCC was reported in a murine model [60]. The gene discussed is KRAS; the disease is hepatocellular carcinoma.